Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. 1979

S Frytak, and C G Moertel, and J R O'Fallon, and J Rubin, and E T Creagan, and M J O'Connell, and A J Schutt, and N W Schwartau

The antiemetic activity and side-effects of delta-9-tetrahydrocannabinol (THC) were evaluated in 116 patients (median age 61 years) receiving combined 5-fluorouracil and semustine (methyl CCNU) therapy for gastrointestinal carcinoma. In a double-blind study, patients were randomized to receive THC, 15 mg orally three times a day, prochlorperazine, 10 mg orally three times a day, or placebo. The THC had superior antiemetic activity in comparison to placebo, but it showed no advantage over prochlorperazine. Central nervous system side-effects, however, were significantly more frequent and more severe with THC. With the dosage and schedule we used, and in our patient population of largely elderly adults, THC therapy resulted in an overall more unpleasant treatment experience than that noted with prochlorperazine or placebo. Although THC may have a role in preventing nausea and vomiting associated with cancer chemotherapy, this role must be more clearly defined before THC can be recommended for general use.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D009607 Nitrosourea Compounds A class of compounds in which the core molecule is R-NO, where R is UREA. Compounds, Nitrosourea
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011346 Prochlorperazine A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612) Compazine,Prochlorperazine Edisylate,Prochlorperazine Edisylate Salt,Prochlorperazine Maleate,Edisylate Salt, Prochlorperazine,Edisylate, Prochlorperazine,Maleate, Prochlorperazine,Salt, Prochlorperazine Edisylate
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005770 Gastrointestinal Neoplasms Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL. Gastrointestinal Cancer,Cancer of Gastrointestinal Tract,Cancer of the Gastrointestinal Tract,Neoplasms, Gastrointestinal,Cancer, Gastrointestinal,Cancers, Gastrointestinal,Gastrointestinal Cancers,Gastrointestinal Neoplasm,Gastrointestinal Tract Cancer,Gastrointestinal Tract Cancers,Neoplasm, Gastrointestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Frytak, and C G Moertel, and J R O'Fallon, and J Rubin, and E T Creagan, and M J O'Connell, and A J Schutt, and N W Schwartau
January 1981, Journal of clinical pharmacology,
S Frytak, and C G Moertel, and J R O'Fallon, and J Rubin, and E T Creagan, and M J O'Connell, and A J Schutt, and N W Schwartau
January 1980, The New England journal of medicine,
S Frytak, and C G Moertel, and J R O'Fallon, and J Rubin, and E T Creagan, and M J O'Connell, and A J Schutt, and N W Schwartau
October 1975, The New England journal of medicine,
S Frytak, and C G Moertel, and J R O'Fallon, and J Rubin, and E T Creagan, and M J O'Connell, and A J Schutt, and N W Schwartau
April 1981, Cancer,
S Frytak, and C G Moertel, and J R O'Fallon, and J Rubin, and E T Creagan, and M J O'Connell, and A J Schutt, and N W Schwartau
May 1981, American journal of hospital pharmacy,
S Frytak, and C G Moertel, and J R O'Fallon, and J Rubin, and E T Creagan, and M J O'Connell, and A J Schutt, and N W Schwartau
June 1980, The New England journal of medicine,
S Frytak, and C G Moertel, and J R O'Fallon, and J Rubin, and E T Creagan, and M J O'Connell, and A J Schutt, and N W Schwartau
June 1980, The New England journal of medicine,
S Frytak, and C G Moertel, and J R O'Fallon, and J Rubin, and E T Creagan, and M J O'Connell, and A J Schutt, and N W Schwartau
June 1980, The New England journal of medicine,
S Frytak, and C G Moertel, and J R O'Fallon, and J Rubin, and E T Creagan, and M J O'Connell, and A J Schutt, and N W Schwartau
June 1979, The New England journal of medicine,
S Frytak, and C G Moertel, and J R O'Fallon, and J Rubin, and E T Creagan, and M J O'Connell, and A J Schutt, and N W Schwartau
November 1980, Archives of internal medicine,
Copied contents to your clipboard!